Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

I was waiting to see if NR could answer your question, but I see he only referred to the data not yet released.

The 48-72 hour 20% reduction is a measure of immediate response in critical cases of ABSSSI. Using the word "critical" I'm referring to the nature of ABSSSI as an uncontrolled infection that when untreated results in further complications, possible loss of limb or even life. An effective antibiotic must stop the spread of the infected area and reduce it by the minimum 20%. Drugs that don't show a quick response to treatment put the patient at continued risk, even if the response is greater after 7 or 10 days. One would not want to administer a drug that allowed continued infection with no subsidence within 3 days even if it were eventually 100% effective. Too many complications from infection remain in play without a significant response in less than 3 days.

The second question you ask regarding 2/3 treatment verses 2/7 or 3/7 is irrelevant to the two drugs. The number of doses has far less to do with sustained response with each dose and more to do with the elimination of the infection. Daptomicin requires 7 days and 7 doses to achieve elimination of the bacterial infection in 98% of people with a nearly zero chance of the infection returning. Brilacidin maybe requires one, though 3 seems certain, for sustained response and a lowest possibility of returning infection.

When a doctor prescribes antibiotics and warns the patient to take all the medicine, it's because most infections respond quickly to the antibiotic and patients may even feel completely cured before the prescription is complete, stop taking the final few doses and then relapse. This possible relapse in spite of appearing successful is the case with Daptomicin. By the 3rd administration the infection is responding rapidly to treatment. The problem is sustained response and elimination any residual bacterial matter still active and might cause relapse.